Mar 10,2023

Cancer Alliances and Careology join forces for a prehabilitation cancer care programme

The East of England Cancer Alliance has funded a new prehabilitation cancer care programme, in partnership with James Paget Hospital, Macmillan Cancer Support and Careology. The programme offers free exercise, advice on diet and nutrition, smoking or alcohol cessation support, and mental wellbeing sessions to all newly-diagnosed cancer patients to prepare them for treatment and help improve their quality of life. Colorectal cancer patients will initially take part in the programme at James Paget as well as lung, melanoma and upper gastrointestinal patients at Mid and South Essex NHS Foundation Trust.

COLLABORATION PARTNERSHIP

#institution

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Mar 09,2023

Could VR therapy improve mental health in cancer patients?

Massachusetts General Hospital in the US has started a clinical trial of a virtual reality (VR) approach to supporting the mental health of patients with cancer, developed by Rocket VR Health. The 80-subject pilot study is testing whether offering immersive therapies and coaching can improve the quality of life of adults diagnosed with blood cancers, as well as alleviate symptoms and reduce psychological distress. The patients are undergoing haematopoietic stem cell transplantation (HCT) – also known as a bone marrow transplant – at MGH, a procedure that requires them to be hospitalised for four weeks or more, often with debilitating side effects from the procedure, like fatigue, loss of appetite, and hair loss. At the heart of the project is a recognition that the mental health issues faced by cancer patients tend to be clinically distinct from other mental health conditions, often a complex mix of fear, sadness, anxiety and depression, and sometimes feelings of guilt and anger.

COLLABORATION PARTNERSHIP

#r&d

#coaching

#connected device

View Analyst & Ambassador Comments
Go to original news
Mar 09,2023

PathAI Announces Early Adoption of its Digital Pathology Platform and Algorithms by Leading Anatomic Pathology Laboratories

PathAI, a global leader in AI-powered pathology, today announced the launch of AISightTM[1], PathAI’s digital pathology platform, and the AIM-PD-L1 NSCLC RUO algorithm1, which quantitates the percent of PD-L1 positive tumor and immune cells in non-small cell lung cancer (NSCLC) samples across the whole slide image (WSI), in 13 leading academic medical centers, health systems, reference laboratories, and independent pathology organizations across the United States. These organizations are part of PathAI’s Early Access Program to gather real-world evidence about the use of digital pathology tools to advance precision medicine for the benefit of patients around the world. AISight is a digital pathology platform that was designed with input from more than 200 pathologists and can be used by physicians, academic institutions, biopharma companies, and CROs to support AI-driven research. The AIM-PD-L1 NSCLC RUO algorithm was built using a series of convolutional neural networks, each trained on a diverse real-world dataset consisting of more than 5,000 samples with inputs from 350,000+ cell and tissue-level annotations from 50+ pathologists.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 08,2023

Coreline Soft bags FDA 510(k) for AI lung cancer detection software

South Korean medtech firm Coreline Soft has obtained the United States Food and Drug Administration's 510(k) clearance for its latest AI-powered analysis software for screening lung nodules. The company develops AI imaging solutions for diagnosing various chest conditions, aortic disease, spinal disease, and metastatic cancer in the chest. Its latest software-as-a-medical device called AVIEW Lung Nodule CAD uses AI to detect lung nodules, which are a major indication of the so-called "big three" diseases: lung cancer, chronic obstructive pulmonary disease, and cardiovascular disease.

REGULATORY FDA

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 08,2023

In Move to Power Precision Oncology for Patients, COTA and Genomic Testing Cooperative Form New Data Partnership

COTA, Inc., an oncology real-world data and analytics company, today announced a new partnership with Genomic Testing Cooperative (GTC), a molecular testing company. The two companies are joining forces to integrate COTA’s deep clinical oncology real-world data with GTC’s comprehensive genomics testing data. This strategic and oncology-specific partnership, grounded in deep comprehensive clinical data, will support more precise, personalized cancer research particularly across early discovery and translational epidemiology functions.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Mar 08,2023

Tempus Introduces TAAP, a Collaborative Research Platform to Develop and Deploy Algorithmic Diagnostics

Tempus, a leader in artificial intelligence and precision medicine, today announced its Tempus AI Advisors Program (TAAP), a platform that provides investigators access to the company’s multimodal database to enable development of novel clinical, molecular, and imaging-based algorithms to improve clinical care. Through TAAP, Tempus is fostering additional research to identify novel clinical biomarkers and use them to develop algorithmic diagnostics that Tempus will validate and make available to physicians for clinical care. The aim of TAAP is to scale the suite of algorithms that can analyze information across multimodal datasets – including pathology, genomics, and radiology – to connect the dots of a patient’s health and unlock new information that may inform their diagnosis, treatment options, or their fitness to participate in a clinical trial. Tempus has already introduced a collection of these algorithmic tests in genetics, including Tempus|TO (Tumor Origin) and Tempus|HRD (Homologous Recombination Deficiency), which are available options with xT, Tempus’ 648-gene, broad-panel sequencing test.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 07,2023

Using ChatGPT to write patient clinic letters

AI, like ChatGPT, has the potential to produce high quality clinical letters that are comprehendible by patients while improving efficiency, consistency, accuracy, patient satisfaction, and deliver cost savings to a health-care system. In this Comment researchers describe the early adoption and evaluation of ChatGPT-generated clinical letters to patients with limited clinical input. They created a series of different clinical communication scenarios that covered the remit of a clinicians' skin cancer practice. 38 hypothetical clinical scenarios were created, seven of which pertained to BCC, 11 to squamous cell carcinoma (SCC), and 20 to malignant melanoma. Overall, the readability scores suggest that the text might be suitable for a varying reading ability, and the mean readability age for the generated letters was at a USA ninth grade (aged 14–15 years) and considered by the US Department of Health and Human Services as average difficulty.

CLINICAL STUDY

#ai/software

#chatbot

View Analyst & Ambassador Comments
Go to original news
Feb 27,2023

Genomics England Deploys Sectra Imaging Technology in Ground-Breaking Cancer Data Programme

Genomics England has completed installation of an enterprise imaging system that will help to support a world-pioneering initiative for cancer research. The programme is linking whole genome sequencing, pathology and radiology data, in what has been described as the world’s largest multimodal cancer research platform. First announced in 2022 as a means to support new discoveries, Genomics England’s programme will help a wide range of researchers and scientists create a better understanding of cancer. It is hoped that this will lead to new treatments as well as supporting the development of cancer-targeting AI. Genomics England has now deployed technology from medical imaging technology provider Sectra, that will play a central role in allowing the organisation to bring together underpinning data, so that researchers and developers from a wide variety of backgrounds can harness it in new ways. In particular, the enterprise imaging system will allow Genomics England to incorporate NHS imaging data, whilst the Image Exchange Portal, a system used nationally in the NHS, will also allow it to transport images from participating NHS trusts.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

View Analyst & Ambassador Comments
Go to original news
Feb 16,2023

Leading Oncology Patient-Reported Outcomes Technology Company Launches Commercialization of Computerized Cancer Symptom Management Pathways

Carevive Systems, Inc., a leading innovator in cancer care management software with a deep real-world evidence patient dataset, announced today that it will launch the commercialization of its computerized cancer symptom management pathways. These pathways were developed through the generous support of a multi-million-dollar Phase I/II Small Business Innovations Research contract funded by the National Cancer Institute. This product took over five years to develop, test, and pilot with input from an international panel of cancer symptom experts. Symptom management is a focus of the Cancer Moonshot Initiative. Carevive is the only company that applied for and received a Fast-Track Phase I/II contract award from the NCI under this research topic. With Carevive PROmpt®, patients are systematically monitored remotely every week, and the care team is notified electronically when patients report symptoms that may require clinical intervention. With the launch of Carevive STAIRS™, when nurses or MAs receive a notification, they can now use structured, decision-tree-based questions when following up with patients to triage and assess symptoms, and the system will offer recommended evidence-based management strategies for consideration.

PRODUCT

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 03,2023

Sussex Researchers use AI to Personalise Cancer Patient Treatments

Researchers at the University of Sussex are using Artificial Intelligence (AI) technology to analyse different types of cancer cells to understand different gene dependencies, and to identify genes that are critical to a cell's survival. Sussex researchers have done this by developing a prediction algorithm that works out which genes are essential in the cell, by analysing the genetic changes in the tumour. This can be used to identify actionable targets that in time could guide oncologists to personalise cancer patient treatments.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY